American BriVision Corporation Appoints Four Additional Members to the Board
November 29, 2017 at 05:02 pm EST
Share
On November 23, 2017, the board of directors of American BriVision (Holding) Corporation appointed four additional members to the Board to fill in the vacancies thereof. The additional board members are Tsang Ming Jiang, Ming-Fong Wu, Norimi Sakamoto and Yen-Hsin Chou. Tsang Ming Jiang, 57 years old, serves as a technical director at the Industrial Technology Research Institute in Taiwan since January 2017. Ming-Fong Wu, 42 years old, is a senior physician at Taoyuan Hanqun Orthopedic Clinic from 2012. Norimi Sakamoto, 47 years old, currently serves at four enterprises, Shogun Maitake Canada Co. Ltd. as an executive officer and business development manager from 2015, Shogun Maitake Odaira Enterprise Ltd. as an executive officer from 2017, Odaira Corporation Co. Ltd. as chief executive officer since 2014 and MyLife Corporation as president and chief executive officer since 2012. Yen-Hsin Chou, 29 years old, serves as a clerk at Mega Securities Co. Ltd. since 2011. Ms. Chou's responsibilities primarily include selling various types of securities, including futures, funds and insurance, managing clients' accounts and business development.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.
ABVC BIOPHARMA, INC. 
